americanpharmaceuticalreviewSeptember 10, 2018
Incyte announced that David Gryska, Executive Vice President and Chief Financial Officer, intends to retire at the end of 2018 and that Incyte has launched a search for his replacement. Gryska plans to remain at Incyte until the end of this year and will provide support during the transitional period.
"Since joining Incyte in 2014, Dave has been an invaluable part of the leadership team. I would like to take this opportunity to thank him for all of his contributions—Dave has helped place Incyte on a firm financial footing, and his expertise has ensured that Incyte has all the necessary systems in place to facilitate our international expansion as we pursue our mission of bringing innovative therapies to patients in need around the world," said Hervé Hoppenot, Chief Executive Officer, Incyte. "As we wish Dave all the best for a long and healthy retirement, we look forward to welcoming his successor who will help us navigate our exciting future as we seek to build a fast-growing, profitable, global biopharmaceutical company."
-----------------------------------------------------------------------------
Editor's Note:
To apply for becoming a contributor of En-CPhI.cn,
welcome to send your CV and sample works to us,
Email: Julia.Zhang@ubmsinoexpo.com.
Contact Us
Tel: (+86) 400 610 1188
WhatsApp/Telegram/Wechat: +86 13621645194
Follow Us: